Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
2015 1
2016 2
2017 2
2019 1
2020 3
2021 4
2022 3
2023 4

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Wemimo
Page 1
Treatment of Metastatic Colorectal Cancer: ASCO Guideline.
Morris VK, Kennedy EB, Baxter NN, Benson AB 3rd, Cercek A, Cho M, Ciombor KK, Cremolini C, Davis A, Deming DA, Fakih MG, Gholami S, Hong TS, Jaiyesimi I, Klute K, Lieu C, Sanoff H, Strickler JH, White S, Willis JA, Eng C. Morris VK, et al. J Clin Oncol. 2023 Jan 20;41(3):678-700. doi: 10.1200/JCO.22.01690. Epub 2022 Oct 17. J Clin Oncol. 2023. PMID: 36252154 Free PMC article.
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.
Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Schneider BJ, et al. J Clin Oncol. 2021 Dec 20;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1. J Clin Oncol. 2021. PMID: 34724392
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.
Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M. Santomasso BD, et al. J Clin Oncol. 2021 Dec 10;39(35):3978-3992. doi: 10.1200/JCO.21.01992. Epub 2021 Nov 1. J Clin Oncol. 2021. PMID: 34724386
RECOMMENDATIONS: The multidisciplinary team issued recommendations to aid in the recognition, workup, evaluation, and management of the most common CAR T-cell-related toxicities, including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, B …
RECOMMENDATIONS: The multidisciplinary team issued recommendations to aid in the recognition, workup, evaluation, and management of the most …
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
Current Status of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma.
Jindal V, Khoury J, Gupta R, Jaiyesimi I. Jindal V, et al. Am J Clin Oncol. 2020 May;43(5):371-377. doi: 10.1097/COC.0000000000000669. Am J Clin Oncol. 2020. PMID: 31990758 Review.
The success of CAR T-cell therapy in lymphoid malignancies encouraged its development in MM. Most of the clinical studies target B-cell maturation antigen in relapsed refractory MM and relapse is the major issue. ...
The success of CAR T-cell therapy in lymphoid malignancies encouraged its development in MM. Most of the clinical studies target B-ce …
Fungal infections in hematopoietic stem-cell transplant patients: a review of epidemiology, diagnosis, and management.
Rahi MS, Jindal V, Pednekar P, Parekh J, Gunasekaran K, Sharma S, Stender M, Jaiyesimi IA. Rahi MS, et al. Ther Adv Infect Dis. 2021 Aug 19;8:20499361211039050. doi: 10.1177/20499361211039050. eCollection 2021 Jan-Dec. Ther Adv Infect Dis. 2021. PMID: 34434551 Free PMC article. Review.
The directed treatment has seen a significant shift from amphotericin B to itraconazole, voriconazole, and echinocandins, which have shown better efficacy and fewer adverse effects. ...
The directed treatment has seen a significant shift from amphotericin B to itraconazole, voriconazole, and echinocandins, which have …
Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise.
Foluso O, Glick A, Stender M, Jaiyesimi I. Foluso O, et al. Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):63-9. doi: 10.1016/j.clml.2015.11.011. Epub 2015 Nov 22. Clin Lymphoma Myeloma Leuk. 2016. PMID: 26775273 Review.
The recent discovery of the role of the B-cell antigen receptor (BCR) signaling pathway in the propagation and maintenance of both normal B-cell function and in B-cell malignancies has highlighted the importance of many protein kinases involved in BCR signal …
The recent discovery of the role of the B-cell antigen receptor (BCR) signaling pathway in the propagation and maintenance of both no …
Metabolomics Analysis of Bacterial Pathogen Burkholderia thailandensis and Mammalian Host Cells in Co-culture.
Aiosa N, Sinha A, Jaiyesimi OA, da Silva RR, Branda SS, Garg N. Aiosa N, et al. ACS Infect Dis. 2022 Aug 12;8(8):1646-1662. doi: 10.1021/acsinfecdis.2c00233. Epub 2022 Jun 29. ACS Infect Dis. 2022. PMID: 35767828
Transcriptomic- and proteomic-based methodologies have been used to investigate mechanisms of virulence employed by B. pseudomallei and Burkholderia thailandensis, a convenient surrogate; however, analysis of the pathogen and host metabolomes during infection is lacking. . …
Transcriptomic- and proteomic-based methodologies have been used to investigate mechanisms of virulence employed by B. pseudomallei a …
Advances in therapy for hairy cell leukemia. A review.
Jaiyesimi IA, Kantarjian HM, Estey EH. Jaiyesimi IA, et al. Cancer. 1993 Jul 1;72(1):5-16. doi: 10.1002/1097-0142(19930701)72:1<5::aid-cncr2820720104>3.0.co;2-y. Cancer. 1993. PMID: 7685243 Review.
BACKGROUND: Hairy cell leukemia (HCL) is a chronic B-cell malignancy, typically seen in middle-aged men, characterized by pancytopenia, splenomegaly, immunologic abnormalities, and morphologically typical neoplastic mononuclear cells in the blood, bone marrow, liver, splee …
BACKGROUND: Hairy cell leukemia (HCL) is a chronic B-cell malignancy, typically seen in middle-aged men, characterized by pancytopeni …
Differences in Cystic Fibrosis-Associated Burkholderia spp. Bacteria Metabolomes after Exposure to the Antibiotic Trimethoprim.
McAvoy AC, Jaiyesimi O, Threatt PH, Seladi T, Goldberg JB, da Silva RR, Garg N. McAvoy AC, et al. ACS Infect Dis. 2020 May 8;6(5):1154-1168. doi: 10.1021/acsinfecdis.9b00513. Epub 2020 Apr 1. ACS Infect Dis. 2020. PMID: 32212725
We investigated the metabolomics differences between three most prevalent Burkholderia spp. associated with cystic fibrosis: B. cenocepacia, B. multivorans, and B. dolosa in the presence and absence of the antibiotic trimethoprim. ...
We investigated the metabolomics differences between three most prevalent Burkholderia spp. associated with cystic fibrosis: B. cenoc …
19 results